PacBio Announces Preliminary Fourth Quarter and Full Year Revenue

Core Insights - PacBio reported preliminary unaudited revenue for Q4 2024 of $39.2 million, a decline of 33$154.0 million, down 23% from the previous year [1][6] - The company launched the Vega benchtop system and SPRQ chemistry, aimed at making HiFi sequencing more accessible and affordable [1][7] - CEO Christian Henry expressed optimism about market share growth in 2025 and noted positive early feedback on new products [2] Business Updates - The Vega system is designed to broaden access to HiFi long-read sequencing [7] - SPRQ chemistry enables sequencing of the human genome for under $500, significantly reducing DNA input requirements [7] - PacBio has begun delivering Vega systems to Berry Genomics for prenatal health and screening programs [7] Financial Position - The company strengthened its balance sheet by exchanging$459 million in convertible senior notes for $200 million in new notes due in August 2029, along with 20.5 million shares and$50 million in cash [7] - Preliminary instrument revenue for Q4 2024 is expected to be approximately $15.3 million, down from$35.1 million in Q4 2023, with 23 Revio and 7 Vega systems sold [7] - Preliminary consumables revenue for Q4 2024 is expected to be around $18.8 million, slightly down from$18.9 million in the same period last year [7] - Total preliminary unrestricted cash and investments as of December 31, 2024, is expected to be approximately $390 million [7]